High dose rate brachytherapy for lip cancer with interstitial, surface, or a combination of interstitial and surface mold technique
Brachytherapy · 2025
DOI: 10.1016/j.brachy.2024.09.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2025. Verfasst von Serhii Brovchuk und 4 weiteren Autor:innen. Beteiligte Einrichtung: Radiotherapy Department, Kyiv Regional Oncology Dispensary, Kyiv, Ukraine; Radiotherapy Department, LISOD Israeli cancer care hospital, Kyiv, Ukraine. Hauptthemen laut MEDLINE: Brachytherapy, Lip Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: High-dose-rate brachytherapy (HDR-BT) is now becoming more common than low-dose-rate and pulsed-dose-rate BT in the treatment of lip cancer. However, due to the limited history of HDR-BT, relatively few studies have been published. Two institutions (in Ukraine and the USA) reviewed their clinical outcomes of lip cancer patients treated with HDR-BT as monotherapy or in combination with external beam radiotherapy (EBRT). METHODS AND MATERIALS: An interstitial (IS), surface custom mold (SC), or a combination of IS and SC (IS+SC) was used for treatments based on the depth of tumor invasion. Prescription doses were 24 Gy in 6 BID fractions when combined with 46-50 Gy of EBRT, 45-55 Gy in 9-10 BID fractions for IS and IS+SC monotherapy or 3 Gy × 16 daily fractions for SC monotherapy. RESULTS: A total of 33 cases of lip cancer were treated from 2015 to 2021. By using TNM staging classification, there were 14 stage I (42.4%), 15 stage II (45.5%), and 4 stage III (12.1%) lip cancers. Thirty-one patients (93.9%) had a complete response to the treatment. Only 2 patients (6.1%) displayed local recurrence. Grade 1, 2, and 3 acute toxicities were observed in 30.3%, 51.5%, and 18.2% of patients, respectively. Grade 1, 2, and 3 late toxicities were observed in 39.4%, 21.2%, and 0.0% of cases. Cosmetic results were excellent in 21.2%, good in 54.5%, fair in 18.2%, and poor in 6.1% of patients. CONCLUSIONS: HDR-BT is an effective and safe treatment for lip carcinomas with excellent local control, functional, and cosmetic outcomes and should be considered as a standard treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Radiotherapy Department, Kyiv Regional Oncology Dispensary, Kyiv, Ukraine; Radiotherapy Department, LISOD Israeli cancer care hospital, Kyiv, Ukraine.
- Radiotherapy Department, Kyiv Regional Oncology Dispensary, Kyiv, Ukraine; Shalimov National Scientific Center of Surgery and Transplantology, Kyiv, Ukraine.
- Department of Radiation Oncology, University of California Los Angeles, Los Angeles, USA.
- Radiotherapy Department, Kyiv Regional Oncology Dispensary, Kyiv, Ukraine.
- Department of Radiation Oncology, University of California Los Angeles, Los Angeles, USA. Electronic address: spark@mednet.ucla.edu.
Zitieren
APA
Brovchuk, S., Shepil, Z., Venkat, P., Vaskevych, O., & Park, S. J. (2025). High dose rate brachytherapy for lip cancer with interstitial, surface, or a combination of interstitial and surface mold technique. Brachytherapy. https://doi.org/10.1016/j.brachy.2024.09.004
Vancouver
Brovchuk S, Shepil Z, Venkat P, Vaskevych O, Park SJ. High dose rate brachytherapy for lip cancer with interstitial, surface, or a combination of interstitial and surface mold technique. Brachytherapy. 2025. doi:10.1016/j.brachy.2024.09.004
BibTeX
@article{Brovchuk2025,
author = {Brovchuk, Serhii and Shepil, Zoia and Venkat, Puja and Vaskevych, Oleg and Park, Sang-June},
title = {High dose rate brachytherapy for lip cancer with interstitial, surface, or a combination of interstitial and surface mold technique},
journal = {Brachytherapy},
year = {2025},
doi = {10.1016/j.brachy.2024.09.004}
}
EUVIMED